Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 04:07 pm EST
Share
Formosa Laboratories, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 1,024.04 million compared to TWD 689.67 million a year ago. Net income was TWD 492.08 million compared to net loss of TWD 384.56 million a year ago. Basic earnings per share from continuing operations was TWD 4.09 compared to basic loss per share from continuing operations of TWD 3.2 a year ago. Diluted earnings per share from continuing operations was TWD 4.09 compared to diluted loss per share from continuing operations of TWD 3.2 a year ago.
For the nine months, sales was TWD 2,697.2 million compared to TWD 2,253.3 million a year ago. Net income was TWD 83.2 million compared to TWD 1,425.88 million a year ago. Basic earnings per share from continuing operations was TWD 0.69 compared to TWD 12.69 a year ago. Diluted earnings per share from continuing operations was TWD 0.69 compared to TWD 11.76 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.